The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021
FY2022 (April 1, 2021 – June 30, 2021) [UNAUDITED]
August 3, 2021
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
https://www.takara-bio.co.jp
Koichi Nakao, President
Takuya Kakemi, Executive Officer, President of Corporate
Management Division
Tel. (077) 565-6970
Scheduled date of quarterly statement filing:
August 6, 2021
Scheduled date of starting delivery of dividends:
Supplementary documents of the financial results:
Yes
Financial results information meeting:No
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

1. Results for the three months ended June 30, 2021 (Apr. 1, 2021 – Jun. 30, 2021)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Three months ended
Jun. 30, 2021

Net sales
Operating profit
Ordinary profit
Net income (loss) attributable to owners ofparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
(Note) Comprehensive income(Millions of yen)
15,272
8,504
8,579
6,025

(2) Consolidated financial position
Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

50.04
8,210

Three months ended
Jun. 30, 2020

(%)

(%)

120.1
-

(Millions of yen)
6,938
693
745
404

(19.8)(69.2)(66.1)(74.6)

(-%)

3.36
(48)

(-%)

As of Jun. 30, 2021
(Millions of yen)

As of Mar 31, 2021
(Millions of yen)

99,65880,58680.7
668.0180,43889,75074,30282.7
616.0574,181

2. Dividends
Year ended
Mar. 31, 2021

Year ended
Mar. 31, 2022

Annual dividends per share in yen
Year ending
Mar. 31, 2022 (Forecast)First quarter end－－
Second quarter end
0.00
Third quarter end－
Year end
16.00
Annual16.00(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes

0.00
－

20.00
20.00

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
3. Forecast for the year ending March 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)(Percentages indicated changes from the same period of the previous fiscal year.)Six months ending
Sep. 30, 2021

(Millions of yen)

Year ending
Mar. 31, 2022(%)

(Millions of yen)
54,20017,00017,10011,90098.82

Net sales
29,70070.8
Operating profit
11,400205.1
Ordinary profit
11,400198.4
Net income attributable to owners of the parent
7,900
247.3
Net income per share (in yen)
65.61
[Note] Revision of financial forecast since the most recently announced payment forecast: Yes
※

(%)
17.6
21.8
20.8
24.6

Others(1) Changes in subsidiaries during the three months ended June 30, 2021
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: － (Name)
Excluded: － (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements: No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： Yes
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No
NOTE: For details, please refer to "(4) Notes to Consolidated Quarterly Financial Statements (Changes in
Accounting Policies)" of "2. Consolidated Quarterly Financial Statements and Primary Notes" on page 9 of theattached material.
(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of June 30, 2021
As of March 31, 2021
120,415,600
2) Number of treasury stocks at year end
As of June 30, 2021
As of March 31, 2021
3) Average number of outstanding shares
120,415,600
As of June 30, 2021
120,415,600
As of June 30, 2020※※

These quarterly financial statements are not subject to auditing.
Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts
due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative
Information for the three months ended June 30, 2021 (4) Qualitative Information Regarding Consolidated Forecasts on
page 2 of the attached document.

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
Contents of the attached document
1. Overview of Financial Results for the three months ended June 30, 2021…………...........…………………………..........
2(1) Overview of Financial Results……………………………………………………….………….………….…………......
2(2) Overview of Financial Position………………………………………………...…………………………...……..............
2(3) Overview of Cash Flows…………………………………………………………….…………………………….……....
2(4) Qualitative Information Regarding Consolidated Forecasts..……………………………………………………………..
2
2. Consolidated Quarterly Financial Statements and Primary Notes............................................................................................. 4(1) Consolidated Quarterly Balance Sheets………………………………………………………………………...................
4(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income..........
6(Consolidated Quarterly Statements of Profit or Loss)(For the Three Months Ended June 30, 2021)…………………………………………………………………...........
6(Consolidated Quarterly Statements of Comprehensive Income)(For Three Months Ended June 30, 2021)…………………………………………………………………………….
7(3) Consolidated Quarterly Statements of Cash Flow ………………………………………………………………………..
8(4) Notes to Consolidated Quarterly Financial Statements……………………………………………………………………
9(Notes on Premise of Going Concern) …………………………………………………………………………………..
9(Notes in case of Changes in Marked Amount of Shareholders’ Equity)………………………………………………..
9(Changes in Subsidiaries during the three months ended June 30, 2021) ………………………………………………
9(Changes in Accounting Policies) ………………………………………………..…………..…………..………….….
9(Additional Information)………………………………………………..…………..…………..…………..………….... 9(Segment Information)……………………………………………………………………………..……………….……
9(Significant Subsequent Events) ………………………………………………………………………………………...
9
3. Supplementary Information…………………………………………………………………………………………………... 10(1) Trends in Key Indicators for Business Management……………………………………………………………………... 10(2) Comparative Consolidated Statement of Income ……………………………………………………………………….... 11(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecast…………………………………………... 12- 1 -The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
1. Overview of Financial Results for the three months ended June 30, 2021
(1) Overview of Financial Results
The outlook for the global economy in the first quarter of the current fiscal year is uncertain due to the prolonged trade friction
between the U.S. and China and the impact of the new Coronavirus disease (COVID-19).
Against these circumstances, Takara Bio (the Group) is promoting the initiatives to advance the development of fundamental
bio-drug discovery technologies and become a drug discovery company that continuously creates new modalities through thereagents, instruments and the CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal
2026, and the three-year Medium-Term Management Plan 2023, which ends in fiscal 2023 1.
In the first quarter of the fiscal year under review, although the sales of Gene Therapy decreased year on year, the sales ofReagents, Instruments, and CDMO increased year on year. In Reagents and Instruments, PCR testing-related products for the newCoronavirus contributed to the increase. As a result, net sales increased to ¥15,272 million (220.1% compared with the same
period of the previous fiscal year). The cost of sales decreased to ¥2,133 million (95.5% compared to the same period of theprevious fiscal year) due to a change in the sales mix and an improvement in the production utilization rate. As a result, grossprofit increased to ¥13,138 million (279.3% compared to the same period of the previous fiscal year). Selling, general andadministrative (SG&A) expenses amounted to ¥4,633 million (115.6% compared with the same period of the previous fiscal
year), mainly due to an increase in personnel expenses and R&D expenses. Operating income increased to ¥8,504 million(1225.5% compared with the same period of the previous fiscal year).
As a result of the increase in operating income, ordinary income increased 1150.8% to ¥8,579 million, income before income
taxes and minority interests increased to 1162.3% to ¥8,561 million, and net income attributable to owners of the parent increased
1491.0% to ¥6,025 million.
Since the Group is a single segment, the description by segment is omitted.
(2) Overview of Financial Position
Total assets at the end of the first quarter under review were ¥99,658 million, an increase of ¥9,907 million from the end of theprevious fiscal year. This was mainly due to an increase of ¥5,492 million in cash and deposits, and an increase of ¥3,151 million
in property, plant and equipment resulting from interior finishing work of Takara Bio USA, Inc.'s new office buildings and ouracquisition of manufacturing facilities.
Total liabilities at the end of the first quarter of the current fiscal year were ¥19,071 million, an increase of ¥3,623 million fromthe end of the previous fiscal year. This was mainly due to an increase of ¥4,385 million in other current liabilities and a decreaseof ¥761 million in income taxes payable.
Total net assets at the end of the first quarter under review were ¥80,586 million, an increase of ¥6,283 million from the end of
the previous fiscal year. This was mainly due to an increase of ¥4,099 million in retained earnings and an increase of ¥2,145
million in foreign currency translation adjustments due to the yen's depreciation.
(3) Overview of Cash FlowsNet cash provided by operating activities amounted to ¥5,604 million, an increase of ¥2,193 million from the same period of theprevious fiscal year. This was mainly due to the balance of cash inflow and outflow. Cash inflow were from income before
income taxes and minority interests of ¥8,561 million and depreciation and amortization of ¥808 million. Cash outflow were fromincome taxes paid of ¥3,105 million and a decrease in other current liabilities of ¥948 million.
Net cash provided by investing activities was ¥2,403 million, an increase of ¥3,178 million from the same period of theprevious fiscal year, mainly due to purchase of property, plant and equipment and intangible assets of ¥2,241 million, proceedsfrom withdrawal of time deposits of ¥1,357 million, and proceeds from subsidy receipts of ¥3,349 million.
Net cash used in financing activities amounted to ¥1,881 million, an increase of ¥936 million from the same period of theprevious fiscal year, mainly due to cash dividends paid of ¥1,846 million.
As a result of the above, the balance of cash and cash equivalents at the end of the first quarter of the current fiscal year,
including the effect of exchange rate changes on cash and cash equivalents, increased by ¥6,656 million from the end of theprevious fiscal year to ¥29,965 million.
(4) Qualitative Information Regarding Consolidated Forecasts
The earnings forecast announced in the financial results summary on May 13, 2021 has been revised. For details, please refer to"Notice of Revision of Financial Forecast and Dividend (Dividend Increase)" announced today (August 3, 2021).
For a comparison of the revised consolidated earnings forecasts with the results of the previous fiscal year and the previous
1

FY2026 and FY2023 refer to the fiscal year ending March 2026 and 2023, respectively.

- 2 -The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
earnings forecasts, please refer to the "Comparative Statement of Profit Relating to Consolidated Earnings Forecasts" on page 12
and later.

- 3 -The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)
As of Mar. 31, 2021

AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total non-current assets
Total assets- 4 -As of Jun. 30, 2021

25,993
12,626
4,966
1,316
2,901
1,352
(41)
49,11531,486
12,867
4,943
1,703
3,256
1,320
(39)
55,537

15,670(5,147)
10,522
7,058(3,760)3,297
7,673(5,141)
2,531
8,143
3,756
1,796
(282)
1,514
29,766

16,281(5,465)
10,815
7,554(4,031)
3,523
8,119(5,402)
2,716
8,312
6,043
1,837
(330)
1,506
32,918

6,149
3,224
9,373

6,451
3,292
9,743

1,495
1,495
40,63589,7501,458
1,458
44,12099,658

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(Millions of yen)
As of Jun. 30, 2021

As of Mar. 31, 2021
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Cumulative remeasurements of retirement
benefit
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

- 5 -

2,077
3,146
739
7,228
13,191

1,841
2,384
985
11,613
16,825

800
1,456
2,256
15,448

789
1,456
2,246
19,071

14,96532,89327,08574,945

14,96532,89331,18579,044

(529)

1,616

(234)

(222)

(763)
120
74,30289,7501,393
148
80,58699,658

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income(Consolidated Quarterly Statements of Profit or Loss)(For the three months ended June 30, 2021)(Millions of yen)Three months ended
Jun. 30, 2021

Three months ended
June. 30, 2020
Net sales
Cost of sales
Gross profit
SG&A expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision for doubtful accounts
Other
Total SG&A expenses
Operating profit
Non-operating profit
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating profit
Non-operating expenses
Interest expenses
Rent expenses on real estate
Other
Total non-operating expenses
Ordinary profit
Extraordinary profit
Gain on sale of fixed assets
National subsidies
Total extraordinary profit
Extraordinary losses
Loss on disposal of fixed assets
Asset shrinkage losses
Total extraordinary losses
Profit before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent

- 6 -

6,938
2,234
4,703

15,272
2,133
13,138

1,044
53
1,172
150
1,588
4,009
693

1,211
57
1,294
191
1,878
4,633
8,504

33
4
30
12
81

30
26
32
5
94

6
9
13
29
745

6
12
1
19
8,579

-

0
49
49

8
8
736
226
99
326
410
6
404

17
49
67
8,561
2,462
55
2,517
6,044
18
6,025

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(Consolidated Quarterly Statements of Comprehensive Income)(For the three months ended June 30, 2021)(Millions of yen)Three months ended
Jun. 30, 2021

Three months ended
Jun. 30, 2020
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest

- 7 -

410

6,044

(467)
8
(458)
(48)

2,154
11
2,166
8,210

(48)
0

8,183
27

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(3) Consolidated Quarterly Statements of Cash Flows(Millions of yen)Three months ended
Jun. 30, 2020
Net cash provided by (used in) operating activities
Profit before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in other provision
Increase (decrease) in retirement benefit liabilities
Interest income
Interest expenses
Loss (gain) on sale and retirement of fixed assets
Decrease (increase) in trade receivables-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Subsidies received
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Subsidies received
Other
Net cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period- 8 -Three months ended
Jun. 30, 2021
736
815
21
123
1
241
(0)
(33)
6
8
2,130
(787)
83
494
76
3,918
19
(6)
(520)
3,411

8,561
808
23
120
(4)
221
(11)
(30)
6
17
(9)
(379)
(388)
(948)
44
8,031
13
(6)
(3,105)
671
5,604

(0)
-

(36)
1,357

(652)

(2,241)

0

0

(116)
(6)
(775)

(25)
3,349
(0)
2,403

(910)
(34)
(944)
(147)
1,543
14,462
16,006(1,846)(34)(1,881)
530
6,656
23,30829,965

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No item to report.
(Changes in Subsidiaries during the three months ended June 30, 2021)
From the first quarter of the current fiscal year, Takara Bio UK Ltd, newly established as a 100% subsidiary of Takara Bio Europe
S.A.S. has been included in the scope of consolidation.
(Changes in Accounting Policies)(Application of Accounting Standard for Revenue Recognition)
The Company adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020, hereinafterreferred to as the "Accounting Standard for Revenue Recognition") from the beginning of the first quarter of the current fiscal year
and recognized revenue when control of promised goods or services is transferred to customers in an amount that is expected to bereceived in exchange for those goods or services.
With regard to the application of the Accounting Standard for Revenue Recognition, in accordance with the transitional treatment
stipulated in the provisions of paragraph 84 of the Accounting Standard for Revenue Recognition, the cumulative effect ofretrospectively applying the new accounting policy prior to the beginning of the first quarter of the current fiscal year was added toor deducted from retained earnings at the beginning of the first quarter of the current fiscal year, and a new accounting policy wasapplied from the beginning balance of the current fiscal year.
As a result, there was no impact on the Company's profit and loss for the first quarter of the current fiscal year. In addition, there
is no impact on the balance of retained earnings at the beginning of the fiscal year.
(Additional Information)(Accounting Estimates for the Impact of the COVID-19)
No material changes have been made to the assumptions used in the previous fiscal year, including the future spread and timing of
convergence of the COVID-19.
(Segment Information)[Segment Information]
Since our group is a single segment, this information is omitted.
(Significant Subsequent Events)
Not applicable.

- 9 -The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
3. Supplemental Information(1)Trends in Key Indicators for Business Management
1) Cash Flows

Cash flow from operating
activities
Cash flow from investing
activities
Cash flow from financing
activities
2) Sales Breakdown by Region

Japan(Millions of yen)Three months ended
Three months ended
Year ended
Jun. 30, 2020
Jun 30, 2021
Mar. 31, 2021
(Apr. 1, 2020 – Jun. 30, 2020) (Apr. 1, 2021 – Jun. 30, 2021) (Apr. 1, 2020 – Mar. 31, 2021)
3,411

5,604

13,943

(775)

2,403

(3,778)(944)(1,881)(1,103)(Millions of yen)Three months ended
Three months ended
Year ended
Jun. 30, 2020
Jun 30, 2021
Mar. 31, 2021
(Apr. 1, 2020 – Jun. 30, 2020) (Apr. 1, 2021 – Jun. 30, 2021) (Apr. 1, 2020 – Mar. 31, 2021)
2,490
6,954
20,475

United States

1,992

2,247

7,862

China
Asia excluding Japan and
China
Europe

1,126

3,094

8,415

450

1,748

4,917

788

1,170

3,743

89

56

671

6,938

15,272

46,086

OthersTotal- 10 -

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(2) Comparative Consolidated Statement of Income(Rounded down to one million yen)Three months
ended

Three months
ended

Jun. 30, 2020

Jun. 30, 2021

5,515

12,8737,358

233.4%

166

390

224

234.9%

1,137

1,955

817

171.9%

Y/YchangeY/Y
ratio(Net sales)
Reagents
Instruments
CDMO
Gene therapy

119

53

(65)

44.7%

Total net sales

6,938

15,272

8,333

220.1%Net sales

6,938

15,272

8,333

220.1%

Cost of sales

2,234

2,133

(100)

95.5%

Gross profit

4,703

13,1388,434

279.3%

SG & A expenses(Operating profit and Loss)

4,009

4,633

624

115.6%

Transportation expenses

176

212

35

120.4%

Advertising expenses

20

13

(7)

65.2%

Promotion expenses

90

180

89

199.0%

R&D expenses

1,172

1,294

122

110.4%

Administrative expense, other

2,477

2,792

314

112.7%

Enterprise taxes (external standards taxation)

71

139

68

195.8%

Operating profit

693

8,504

7,810

1225.5%

81

94

13

116.7%(10)(Non-operating income and Expenses)
Non-operating income
Non-operating expenses

29

19

Ordinary profit

745

8,579

Extraordinary income-

49

Extraordinary losses

8

Profit before income taxes and others

65.5%

7,834

1150.8%

49

-

67

58

764.0%

736

8,561

7,825

1162.3%

Income taxes

326

2,517

2,191

772.2%Net income

410

6,044

5,633

1472.0%Net income (loss) attributable to non-controllinginterests

6

18

11

283.0%Net income attributable to owners of the parent

404

6,025

5,621

1491.0%Depreciation and amortization(Property, plant and equipment and intangible assets)

815

808

(7)

99.1%

(Extraordinary income & Losses)

Amortization of goodwill
123
120
(3)
97.4%
※1 From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents","Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

- 11 -

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecasts
1) First half ending Sep. 30, 2021
First halfFirst halfendingendingFirst half
Sep. 30,
Sep.30,Y/Y
ended Sep.
2021
2021
Change30, 2020
Previous
Current
forecast
forecast(Net sales)

Y/Y
Ratio

Previous
forecast
ChangePrevious
forecast
Ratio

Reagents

13,336

19,12824,058

10,721180.4%

4,930

125.8%

Instruments

466

837

790

323

169.4%

(46)

94.4%

CDMO

3,373

4,033

4,727

1,353

140.1%

693

117.2%

Gene therapy

215

610

123

(92)

57.3%

(487)

20.3%

Total Net Sales

17,39324,60929,70012,306170.8%

5,090

120.7%

17,39324,60929,70012,306170.8%

5,090

120.7%(Operating profit and Loss)
Net sales
Cost of sales

5,565

7,948

8,749

3,183

157.2%

800

110.1%

Gross profit

11,827

16,661

20,9509,123

177.1%

4,289

125.7%

SG & A expenses

8,090

9,521

9,550

1,459

118.0%

29

100.3%

Transportation expenses

336

441

425

89

126.7%

(16)

96.4%

Advertising expenses

31

41

29

(1)

94.2%

(12)

69.8%

Promotion expenses
R&D expenses
Administrative expenses, other
Enterprise taxes(external standards taxation)
Operating profit(Non-operating income andExpenses)Non-operating income
Non-operating expenses
Ordinary profit

276

398

434

158

157.5%

36

109.0%

2,403

2,717

2,689

286

111.9%

(27)

99.0%

4,883

5,718

5,767

884

118.1%

49

100.9%

160

203

203

42

126.2%

0

100.0%

3,736

7,139

11,4007,663

305.1%

4,260

159.7%

143

114

135

(7)

94.7%

20

118.3%

59

34

135

75

227.1%

101

397.9%

3,820

7,220

11,4007,579

298.4%

4,180

157.9%

1

2,888

2,992

2,990

-

104

103.6%

539

2,905

3,021

2,482

560.3%

116

104.0%

3,281

7,203

11,3708,088

346.4%

4,167

157.9%

990

2,294

3,426

2,436

346.0%

1,132

149.3%

2,291

4,908

7,943

5,652

346.7%

3,035

161.8%

16

18

43

26

256.3%

24

232.1%

2,274

4,889

7,900

5,625

347.3%

3,010

161.6%

1,631

1,727

1,736

104

106.4%

8

100.5%

246

236

245

(0)

99.6%

8

103.7%(Extraordinary income & Losses)
Extraordinary income
Extraordinary losses
Profit before income taxes andothersIncome taxes
Net income
Net income (loss) attributable
to non-controlling interests
Net income attributable toowners of parent
Depreciation and amortization(Property, plant andequipment and intangible
assets)Amortization of goodwill※1 From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents","Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

- 12 -

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)
2) Year Ending Mar. 31, 2022
Year
ended
Mar. 31,2021
ActualYear
endingMar. 31,2022
Previous
forecast

Year
endingMar. 31,2022
Current
forecast

Reagents

35,18936,801

40,594

Instruments

1,726

1,720

1,542

CDMO

8,901

10,584

11,346

Gene therapy

268

1,393

716

Total Net Sales

46,08650,500Net sales

46,086

Cost of sales

Previous
forecast
ChangePrevious
forecast
Ratio

115.4%

3,793

110.3%

(184)

89.3%

(178)

89.6%

2,444

127.5%

761

107.2%

448

267.0%

(676)

51.4%

54,2008,113

117.6%

3,700

107.3%

50,50054,2008,113

117.6%

3,700

107.3%

14,214

16,482

16,932

2,718

119.1%

449

102.7%

Gross profit

31,87234,01737,2675,394

116.9%

3,250

109.6%

SG & A expenses

17,91920,017

20,2672,347

113.1%

250

101.2%

742

837

831

89

112.0%

(6)

99.3%

Y/Y
ChangeY/Y
Ratio(Net sales)
5,405(Operating profit and Loss)

Transportation expenses
Advertising expenses

57

83

62

5

109.1%

(21)

74.6%

Promotion expenses

676

871

810

134

119.8%

(60)

93.0%

R&D expenses

5,545

5,812

6,003

457

108.3%

190

103.3%

Administrative expenses, other
Enterprise taxes(external standards taxation)
Operating profit(Non-operating income andExpenses)Non-operating income

10,496

12,00312,128

1,632

115.6%

125

101.0%

401

408

430

28

107.1%

21

105.3%

13,952

14,00017,0003,047

121.8%

3,000

121.4%

308

301

258

(49)

84.0%

(43)

85.7%

Non-operating expenses

101

101

158

57

156.9%

56

155.8%

14,15914,20017,1002,940

120.8%

2,900

120.4%

518

4,592

4,780

4,261

921.8%

187

104.1%

1,125

4,651

4,849

3,724

430.9%

197

104.3%

13,552

14,14017,0303,477

125.7%

2,889

120.4%

Ordinary profit(Extraordinary income & Losses)
Extraordinary income
Extraordinary losses
Profit before income taxes andothersIncome taxes
Net income
Net income (loss) attributable
to non-controlling interests
Net income attributable toowners of parent
Depreciation and amortization(Property, plant andequipment and intangible
assets)Amortization of goodwill

3,971

4,314

5,082

1,110

128.0%

767

117.8%

9,581

9,825

11,9482,366

124.7%

2,122

121.6%

34

25

48

14

141.4%

22

188.7%

9,547

9,800

11,9002,352

124.6%

2,100

121.4%

3,220

3,653

3,687

467

114.5%

34

100.9%

486

473

473

(12)

97.4%

0

100.0%※1 From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents","Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

- 13 -